Fibromyalgia and Inflammation: Rethinking Widespread Pain

Fibromyalgia is one of the most prevalent chronic pain conditions, affecting an estimated 2 to 4 percent of the population and disproportionately impacting women. It is characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive difficulties, and heightened sensitivity to stimuli that would not normally cause pain. For most of its recognized history as a diagnosis, fibromyalgia was defined by what it was not: not autoimmune, not structurally degenerative, and critically, not inflammatory. That definition is now undergoing a fundamental revision.

Advances in neuroimaging, cerebrospinal fluid analysis, and molecular biology have revealed that fibromyalgia involves real, measurable biological changes in the nervous system. Central to this emerging picture is neuroinflammation, specifically the activation of glial cells in the spinal cord and brain that amplifies pain signaling far beyond what any peripheral injury could explain.

Central Sensitization: The Pain Amplifier

Rewiring the pain system. In fibromyalgia, the central nervous system develops a state called central sensitization, in which pain processing circuits become abnormally amplified. Stimuli that are ordinarily innocuous, such as light touch or mild pressure, are processed as painful. Actual painful stimuli produce disproportionately intense and prolonged responses. This is not imagined or psychological in origin; it reflects genuine changes in the functional architecture of the central nervous system.

The glial contribution. Microglia and astrocytes, the non-neuronal cells that make up the majority of the central nervous system, play a critical role in central sensitization. When activated, they release glutamate, pro-inflammatory cytokines, and other signaling molecules that lower the activation threshold of pain-sensing neurons and impair the descending inhibitory pathways that normally suppress pain signals. In fibromyalgia, these glial cells appear to remain in a persistently activated state, continuously feeding the sensitized pain network.

Altered neurotransmitter balance. Studies of cerebrospinal fluid in fibromyalgia patients have found elevated levels of substance P (a key pain-signaling neuropeptide) and glutamate, as well as reduced levels of serotonin and norepinephrine, neurotransmitters that contribute to pain inhibition. These changes directly reflect the state of neuroinflammation and its consequences for central nervous system function.

Small Fiber Neuropathy: A Peripheral Inflammatory Component

Nerve fiber loss. A significant subset of fibromyalgia patients has been found to have small fiber neuropathy (SFN), a condition involving loss or dysfunction of the small, unmyelinated nerve fibers that transmit pain and temperature signals and regulate autonomic functions. Several studies using skin punch biopsies have found reduced small fiber density in fibromyalgia patients compared to healthy controls, providing a structural, peripheral correlate to the otherwise centrally-driven condition.

Inflammatory mechanisms in SFN. Small fiber damage in fibromyalgia appears to involve inflammatory and potentially autoimmune mechanisms. Research has identified autoantibodies targeting proteins on dorsal root ganglion neurons in a subset of patients. These autoantibodies can activate immune cells and trigger local inflammatory responses that damage nerve fibers over time, generating the peripheral pain signals that feed and reinforce central sensitization.

Autonomic consequences. Small fiber nerves also regulate blood vessel tone, sweating, and heart rate variability. Their dysfunction in fibromyalgia contributes to the autonomic abnormalities many patients experience, including orthostatic intolerance, temperature dysregulation, and cardiovascular variability, all of which are worsened by inflammatory signaling in the peripheral nervous system.

Systemic Inflammatory Markers in Fibromyalgia

The cytokine picture. Blood-based inflammatory studies in fibromyalgia have been mixed, partly because the condition is heterogeneous and partly because the inflammation may be concentrated in the central nervous system rather than the periphery. However, a number of studies have found elevated IL-6, IL-8, IL-1 beta, and TNF-alpha in fibromyalgia patients compared to controls. A 2019 meta-analysis found consistently elevated IL-6 and IL-8 across multiple studies, suggesting a systemic inflammatory component alongside the central neuroinflammation.

Mast cell activation. There is growing interest in the role of mast cells, immune cells distributed throughout connective tissue and near nerve endings, in fibromyalgia. Mast cells release histamine, tryptase, and various cytokines that can directly sensitize nearby pain neurons. Elevated mast cell activation markers have been found in some fibromyalgia patient groups, and many patients report symptom overlap with mast cell activation syndrome.

Gut microbiome and systemic inflammation. Emerging research has found altered gut microbiome composition in fibromyalgia, with reduced microbial diversity and changes in species associated with inflammation and pain modulation. Gut dysbiosis can drive systemic low-grade inflammation through increased intestinal permeability and altered production of short-chain fatty acids and neuroactive metabolites, providing another pathway through which systemic inflammation may feed fibromyalgia symptoms.

Managing Fibromyalgia Through an Anti-Inflammatory Lens

Exercise with appropriate pacing. Low-intensity aerobic exercise and resistance training have the strongest evidence base for fibromyalgia management. Exercise reduces neuroinflammation, improves descending pain inhibition, and promotes the release of endorphins and other anti-inflammatory signaling molecules. Critically, exercise must be paced carefully to avoid triggering post-exertional flares, gradually increasing load over weeks and months.

Dietary interventions. Anti-inflammatory dietary patterns have shown benefit in several small trials of fibromyalgia patients. Mediterranean-style diets, low in ultra-processed foods and high in omega-3 fatty acids, polyphenols, and fiber, have been associated with reduced pain scores and fatigue ratings. Elimination of common dietary triggers (gluten, dairy, high-fructose corn syrup) may benefit a subset of patients whose symptoms are amplified by food-driven gut inflammation.

Sleep optimization. Fibromyalgia and sleep disruption form a mutually reinforcing cycle: poor sleep worsens pain sensitivity and neuroinflammation, while pain disrupts sleep. Prioritizing sleep quality through consistent sleep schedules, limiting blue light exposure, and addressing sleep apnea where present can meaningfully reduce the inflammatory burden driving fibromyalgia symptoms.

Stress reduction and the HPA axis. Chronic psychological stress activates the HPA axis, elevates cortisol, and promotes neuroinflammation. In fibromyalgia, HPA axis dysregulation is a consistent finding, with abnormal cortisol rhythms and heightened stress reactivity. Mind-body practices including mindfulness meditation, yoga, and cognitive behavioral therapy have demonstrated measurable reductions in fibromyalgia symptom burden through their effects on the stress-inflammation axis.